StemCell Therapy

Telomeres are the protective caps at chromosome ends. In adult cells, telomeres shorten each time a cell divides and this contributes to ageing and cancer. Pluripotent stem cells, however, are specialised cells that exist in the earliest days of development. These pluripotent cells do not age and have the ability to turn into any type of adult cell.

The surprise finding, published today in Nature, shows that telomeres in pluripotent stem cells are protected very differently than telomeres in adult tissues.

This upends 20 years of thinking on how stem cells protect their DNA, said Associate Professor Tony Cesare, from the University of Sydneys Faculty of Medicine and Health, who is Head of the Genome Integrity Unit at Childrens Medical Research Institute (CMRI) and co-leader of a research team that collaborated on this research.

In adult cells, a protein called TRF2 is essential because it arranges DNA at the chromosome end into a telomere-loop structure. Removing TRF2 from adult cells causes the chromosomes to become stitched together into one long string, which is incompatible with life.

To the researchers astonishment, removing TRF2 from pluripotent stem cells did almost nothing. The chromosomes were normal, the telomere-loops remained, and the cells divided as if nothing happened. Telomeres are therefore protected differently in pluripotent stem cells and adult tissues.

This unexpected finding has major implications for research on ageing, human development, regenerative medicine, and cancer. Previously, researchers expected fundamental mechanisms that protected DNA would be the same in all tissues. This now appears to be incorrect.

View original post here:
Unexpected discovery about stem cell immortality study - News - The University of Sydney

Orthopedic Regenerative Medicine Market

Coherent Market Insights, 26-11-2020: The research report on the Orthopedic Regenerative Medicine Market is a deep analysis of the market. This is a latest report, covering the current COVID-19 impact on the market. The pandemic of Coronavirus (COVID-19) has affected every aspect of life globally. This has brought along several changes in market conditions. The rapidly changing market scenario and initial and future assessment of the impact is covered in the report. Experts have studied the historical data and compared it with the changing market situations. The report covers all the necessary information required by new entrants as well as the existing players to gain deeper insight.

Furthermore, the statistical survey in the report focuses on product specifications, costs, production capacities, marketing channels, and market players. Upstream raw materials, downstream demand analysis, and a list of end-user industries have been studied systematically, along with the suppliers in this market. The product flow and distribution channel have also been presented in this research report.

Get a sample pages of this Report:https://www.coherentmarketinsights.com/insight/request-sample/3566

The segments and sub-section of Orthopedic Regenerative Medicine market are shown below:

By Procedure Cell TherapyTissue EngineeringBy Cell TypeInduced Pluripotent Stem Cells (iPSCs)Adult Stem CellsTissue Specific Progenitor Stem Cells (TSPSCs),Mesenchymal Stem Cells (MSCs)Umbilical Cord Stem Cells (UCSCs)Bone Marrow Stem Cells (BMSCs)By SourceBone MarrowUmbilical Cord BloodAdipose TissueAllograftsAmniotic FluidBy ApplicationsTendons RepairCartilage RepairBone RepairLigament RepairSpine RepairOthers

Some of the key players/Manufacturers involved in the Orthopedic Regenerative Medicine Market are Curasan, Inc., Carmell Therapeutics Corporation, Anika Therapeutics, Inc., Conatus Pharmaceuticals Inc., Histogen Inc., Royal Biologics, Ortho Regenerative Technologies, Inc., Swiss Biomed Orthopaedics AG, Osiris Therapeutics, Inc., and Octane Medical Inc.

If opting for the Global version of Orthopedic Regenerative Medicine Market analysis is provided for major regions as follows:

North America (The US, Canada, and Mexico)

Europe (the UK, Germany, France, and Rest of Europe)

Asia Pacific (China, India, and Rest of Asia Pacific)

Latin America (Brazil and Rest of Latin America)

Middle East & Africa (Saudi Arabia, the UAE, South Africa, and Rest of Middle East & Africa)

Buy This Complete A Business Report @:https://www.coherentmarketinsights.com/insight/buy-now/3566

The Orthopedic Regenerative Medicine Market Report Consists of the Following Points:

The report consists of an overall prospect of the market that helps gain significant insights about the global market.

The market has been categorized based on types, applications, and regions. For an in-depth analysis and better understanding of the market, the key segments have been further categorized into sub-segments.

The factors responsible for the growth of the market have been mentioned. This data has been gathered from primary and secondary sources by industry professionals. This provides an in-depth understanding of key segments and their future prospects.

The report analyses the latest developments and the profiles of the leading competitors in the market.

The Orthopedic Regenerative Medicine Market research report offers an eight-year forecast.

Enquire for customization in Report @https://www.coherentmarketinsights.com/insight/request-customization/3566

Interested about who is winning the race of COVID-19 Vaccine. Coherent Market Insights (CMI)

providesCOVID-19 Vaccine Trackerfor all the latest updates about COVID-19 Vaccine.

CMI also offers Custom Research services providing focused, comprehensive and tailored research according to clientele objectives. Thanks for reading this article; you can also get individual chapter wise section or region wise report like North America, Europe or Asia.

About Us:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contacts Us:Direct Line: +1-206-701-6702 (US)Web:https://www.coherentmarketinsights.com

See the article here:
Impact of COVID 19 on Orthopedic Regenerative Medicine Market Detailed Research Study 2020-2027 | Curasan, Inc., Carmell Therapeutics Corporation,...

NEW YORK, Nov. 25, 2020 /PRNewswire/ --Amid the COVID-19 crisis, the global market for Cell Harvesting estimated at US$233.2 Million in the year 2020, is projected to reach a revised size of US$381.4 Million by 2027, growing at a CAGR of 7.3% over the period 2020-2027.Manual, one of the segments analyzed in the report, is projected to grow at a 7.9% CAGR to reach US$284.4 Million by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Automated segment is readjusted to a revised 5.6% CAGR for the next 7-year period. This segment currently accounts for a 28.3% share of the global Cell Harvesting market.

Read the full report: https://www.reportlinker.com/p05798117/?utm_source=PRN

The U.S. Accounts for Over 30.9% of Global Market Size in 2020, While China is Forecast to Grow at a 10.4% CAGR for the Period of 2020-2027

The Cell Harvesting market in the U.S. is estimated at US$72 Million in the year 2020. The country currently accounts for a 30.86% share in the global market. China, the world second largest economy, is forecast to reach an estimated market size of US$34.9 Million in the year 2027 trailing a CAGR of 10.4% through 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 6.1% and 7% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 6.6% CAGR while Rest of European market (as defined in the study) will reach US$34.9 Million by the year 2027.We bring years of research experience to this 5th edition of our report. The 226-page report presents concise insights into how the pandemic has impacted production and the buy side for 2020 and 2021. A short-term phased recovery by key geography is also addressed.

Competitors identified in this market include, among others,

Read the full report: https://www.reportlinker.com/p05798117/?utm_source=PRN

I. INTRODUCTION, METHODOLOGY & REPORT SCOPE I-1

II. EXECUTIVE SUMMARY II-1

1. MARKET OVERVIEW II-1 Cell Harvesting - A Prelude II-1 Impact of Covid-19 and a Looming Global Recession II-1 With Stem Cells Holding Potential to Emerge as Savior for Healthcare System Struggling with COVID-19 Crisis, Demand for Cell Harvesting to Grow II-1 Select Clinical Trials in Progress for MSCs in the Treatment of COVID-19 II-2 Lack of Antiviral Therapy Brings Spotlight on MSCs as Potential Option to Treat Severe Cases of COVID-19 II-3 Stem Cells Garner Significant Attention amid COVID-19 Crisis II-3 Growing R&D Investments & Rising Incidence of Chronic Diseases to Drive the Global Cell Harvesting Market over the Long-term II-3 US Dominates the Global Market, Asia-Pacific to Experience Lucrative Growth Rate II-4 Biopharmaceutical & Biotechnology Firms to Remain Key End-User II-4 Remarkable Progress in Stem Cell Research Unleashes Unlimited Avenues for Regenerative Medicine and Drug Development II-4 Drug Development II-5 Therapeutic Potential II-5

2. FOCUS ON SELECT PLAYERS II-6 Recent Market Activity II-7 Innovations and Advancements II-7

3. MARKET TRENDS & DRIVERS II-8 Development of Regenerative Medicine Accelerates Demand for Cell Harvesting II-8 The Use of Mesenchymal Stem Cells in Regenerative Medicine to Drive the Cell Harvesting Market II-8 Rise in Volume of Orthopedic Procedures Boosts Prospects for Stem Cell, Driving the Cell Harvesting II-9 Exhibit 1: Global Orthopedic Surgical Procedure Volume (2010- 2020) (in Million) II-11 Increasing Demand for Stem Cell Based Bone Grafts: Promising Growth Ahead for Cell Harvesting II-11 Spectacular Advances in Stem Cell R&D Open New Horizons for Regenerative Medicine II-12 Exhibit 2: Global Regenerative Medicines Market by Category (2019): Percentage Breakdown for Biomaterials, Stem Cell Therapies and Tissue Engineering II-13 Stem Cell Transplants Drive the Demand for Cell Harvesting II-13 Rise in Number of Hematopoietic Stem Cell Transplantation Procedures Propels Market Expansion II-15 Growing Incidence of Chronic Diseases to Boost the Demand for Cell Harvesting II-16 Exhibit 3: Global Cancer Incidence: Number of New Cancer Cases in Million for the Years 2018, 2020, 2025, 2030, 2035 and 2040 II-17 Exhibit 4: Global Number of New Cancer Cases and Cancer-related Deaths by Cancer Site for 2018 II-18 Exhibit 5: Number of New Cancer Cases and Deaths (in Million) by Region for 2018 II-19 Exhibit 6: Fatalities by Heart Conditions: Estimated Percentage Breakdown for Cardiovascular Disease, Ischemic Heart Disease, Stroke, and Others II-19 Exhibit 7: Rising Diabetes Prevalence Presents Opportunity for Cell Harvesting: Number of Adults (20-79) with Diabetes (in Millions) by Region for 2017 and 2045 II-20 Ageing Demographics to Drive Demand for Stem Cell Banking II-20 Global Aging Population Statistics - Opportunity Indicators II-21 Exhibit 8: Expanding Elderly Population Worldwide: Breakdown of Number of People Aged 65+ Years in Million by Geographic Region for the Years 2019 and 2030 II-21 Exhibit 9: Life Expectancy for Select Countries in Number of Years: 2019 II-22 High Cell Density as Major Bottleneck Leads to Innovative Cell Harvesting Methods II-22 Advanced Harvesting Systems to Overcome Centrifugation Issues II-23 Sophisticated Filters for Filtration Challenges II-23 Innovations in Closed Systems Boost Efficiency & Productivity of Cell Harvesting II-23 Enhanced Harvesting and Separation of Micro-Carrier Beads II-24

4. GLOBAL MARKET PERSPECTIVE II-25 Table 1: World Current & Future Analysis for Cell Harvesting by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 II-25

Table 2: World Historic Review for Cell Harvesting by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 II-26

Table 3: World 15-Year Perspective for Cell Harvesting by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2012, 2020 & 2027 II-27

Table 4: World Current & Future Analysis for Manual by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 II-28

Table 5: World Historic Review for Manual by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 II-29

Table 6: World 15-Year Perspective for Manual by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 II-30

Table 7: World Current & Future Analysis for Automated by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 II-31

Table 8: World Historic Review for Automated by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 II-32

Table 9: World 15-Year Perspective for Automated by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 II-33

Table 10: World Current & Future Analysis for Peripheral Blood by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 II-34

Table 11: World Historic Review for Peripheral Blood by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 II-35

Table 12: World 15-Year Perspective for Peripheral Blood by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 II-36

Table 13: World Current & Future Analysis for Bone Marrow by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 II-37

Table 14: World Historic Review for Bone Marrow by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 II-38

Table 15: World 15-Year Perspective for Bone Marrow by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 II-39

Table 16: World Current & Future Analysis for Umbilical Cord by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 II-40

Table 17: World Historic Review for Umbilical Cord by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 II-41

Table 18: World 15-Year Perspective for Umbilical Cord by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 II-42

Table 19: World Current & Future Analysis for Adipose Tissue by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 II-43

Table 20: World Historic Review for Adipose Tissue by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 II-44

Table 21: World 15-Year Perspective for Adipose Tissue by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 II-45

Table 22: World Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 II-46

Table 23: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 II-47

Table 24: World 15-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 II-48

Table 25: World Current & Future Analysis for Biotech & Biopharma Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 II-49

Table 26: World Historic Review for Biotech & Biopharma Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 II-50

Table 27: World 15-Year Perspective for Biotech & Biopharma Companies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 II-51

Table 28: World Current & Future Analysis for Research Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 II-52

Table 29: World Historic Review for Research Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 II-53

Table 30: World 15-Year Perspective for Research Institutes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 II-54

Table 31: World Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 II-55

Table 32: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 II-56

Table 33: World 15-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 II-57

III. MARKET ANALYSIS III-1

GEOGRAPHIC MARKET ANALYSIS III-1

UNITED STATES III-1 Increasing Research on Stem Cells for Treating COVID-19 to drive the Cell Harvesting Market III-1 Rising Investments in Stem Cell-based Research Favors Cell Harvesting Market III-1 Exhibit 10: Stem Cell Research Funding in the US (in US$ Million) for the Years 2011 through 2017 III-2 A Strong Regenerative Medicine Market Drives Cell Harvesting Demand III-2 Arthritis III-3 Exhibit 11: Percentage of Population Diagnosed with Arthritis by Age Group III-3 Rapidly Ageing Population: A Major Driving Demand for Cell Harvesting Market III-4 Exhibit 12: North American Elderly Population by Age Group (1975-2050) III-4 Increasing Incidence of Chronic Diseases Drives Focus onto Cell Harvesting III-5 Exhibit 13: CVD in the US: Cardiovascular Disease* Prevalence in Adults by Gender & Age Group III-5 Rising Cancer Cases Spur Growth in Cell Harvesting Market III-5 Exhibit 14: Estimated Number of New Cancer Cases and Deaths in the US (2019) III-6 Exhibit 15: Estimated New Cases of Blood Cancers in the US (2020) - Lymphoma, Leukemia, Myeloma III-7 Exhibit 16: Estimated New Cases of Leukemia in the US: 2020 III-7 Market Analytics III-8 Table 34: USA Current & Future Analysis for Cell Harvesting by Type - Manual and Automated - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 III-8

Table 35: USA Historic Review for Cell Harvesting by Type - Manual and Automated Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 III-9

Table 36: USA 15-Year Perspective for Cell Harvesting by Type - Percentage Breakdown of Value Sales for Manual and Automated for the Years 2012, 2020 & 2027 III-10

Table 37: USA Current & Future Analysis for Cell Harvesting by Application - Peripheral Blood, Bone Marrow, Umbilical Cord, Adipose Tissue and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 III-11

Table 38: USA Historic Review for Cell Harvesting by Application - Peripheral Blood, Bone Marrow, Umbilical Cord, Adipose Tissue and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 III-12

Table 39: USA 15-Year Perspective for Cell Harvesting by Application - Percentage Breakdown of Value Sales for Peripheral Blood, Bone Marrow, Umbilical Cord, Adipose Tissue and Other Applications for the Years 2012, 2020 & 2027 III-13

Table 40: USA Current & Future Analysis for Cell Harvesting by End-Use - Biotech & Biopharma Companies, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 III-14

Table 41: USA Historic Review for Cell Harvesting by End-Use - Biotech & Biopharma Companies, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 III-15

Table 42: USA 15-Year Perspective for Cell Harvesting by End-Use - Percentage Breakdown of Value Sales for Biotech & Biopharma Companies, Research Institutes and Other End-Uses for the Years 2012, 2020 & 2027 III-16

CANADA III-17 Market Overview III-17 Exhibit 17: Number of New Cancer Cases in Canada: 2019 III-17 Market Analytics III-18 Table 43: Canada Current & Future Analysis for Cell Harvesting by Type - Manual and Automated - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 III-18

Table 44: Canada Historic Review for Cell Harvesting by Type - Manual and Automated Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 III-19

Table 45: Canada 15-Year Perspective for Cell Harvesting by Type - Percentage Breakdown of Value Sales for Manual and Automated for the Years 2012, 2020 & 2027 III-20

Table 46: Canada Current & Future Analysis for Cell Harvesting by Application - Peripheral Blood, Bone Marrow, Umbilical Cord, Adipose Tissue and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 III-21

Table 47: Canada Historic Review for Cell Harvesting by Application - Peripheral Blood, Bone Marrow, Umbilical Cord, Adipose Tissue and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 III-22

Table 48: Canada 15-Year Perspective for Cell Harvesting by Application - Percentage Breakdown of Value Sales for Peripheral Blood, Bone Marrow, Umbilical Cord, Adipose Tissue and Other Applications for the Years 2012, 2020 & 2027 III-23

Table 49: Canada Current & Future Analysis for Cell Harvesting by End-Use - Biotech & Biopharma Companies, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 III-24

Table 50: Canada Historic Review for Cell Harvesting by End-Use - Biotech & Biopharma Companies, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 III-25

Table 51: Canada 15-Year Perspective for Cell Harvesting by End-Use - Percentage Breakdown of Value Sales for Biotech & Biopharma Companies, Research Institutes and Other End-Uses for the Years 2012, 2020 & 2027 III-26

JAPAN III-27 Increasing Demand for Regenerative Medicine in Geriatric Healthcare and Cancer Care to Drive Demand for Cell Harvesting III-27 Exhibit 18: Japanese Population by Age Group (2015 & 2040): Percentage Share Breakdown of Population for 0-14, 15-64 and 65 & Above Age Groups III-27 Exhibit 19: Cancer Related Incidence and Deaths by Site in Japan: 2018 III-28 Market Analytics III-29 Table 52: Japan Current & Future Analysis for Cell Harvesting by Type - Manual and Automated - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 III-29

Table 53: Japan Historic Review for Cell Harvesting by Type - Manual and Automated Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 III-30

Table 54: Japan 15-Year Perspective for Cell Harvesting by Type - Percentage Breakdown of Value Sales for Manual and Automated for the Years 2012, 2020 & 2027 III-31

Table 55: Japan Current & Future Analysis for Cell Harvesting by Application - Peripheral Blood, Bone Marrow, Umbilical Cord, Adipose Tissue and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 III-32

Table 56: Japan Historic Review for Cell Harvesting by Application - Peripheral Blood, Bone Marrow, Umbilical Cord, Adipose Tissue and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 III-33

Table 57: Japan 15-Year Perspective for Cell Harvesting by Application - Percentage Breakdown of Value Sales for Peripheral Blood, Bone Marrow, Umbilical Cord, Adipose Tissue and Other Applications for the Years 2012, 2020 & 2027 III-34

Table 58: Japan Current & Future Analysis for Cell Harvesting by End-Use - Biotech & Biopharma Companies, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 III-35

Table 59: Japan Historic Review for Cell Harvesting by End-Use - Biotech & Biopharma Companies, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 III-36

Table 60: Japan 15-Year Perspective for Cell Harvesting by End-Use - Percentage Breakdown of Value Sales for Biotech & Biopharma Companies, Research Institutes and Other End-Uses for the Years 2012, 2020 & 2027 III-37

CHINA III-38 Rising Incidence of Cancer Drives Cell Harvesting Market III-38 Exhibit 20: Number of New Cancer Cases Diagnosed (in Thousands) in China: 2018 III-38 Market Analytics III-39 Table 61: China Current & Future Analysis for Cell Harvesting by Type - Manual and Automated - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 III-39

Table 62: China Historic Review for Cell Harvesting by Type - Manual and Automated Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 III-40

Table 63: China 15-Year Perspective for Cell Harvesting by Type - Percentage Breakdown of Value Sales for Manual and Automated for the Years 2012, 2020 & 2027 III-41

Table 64: China Current & Future Analysis for Cell Harvesting by Application - Peripheral Blood, Bone Marrow, Umbilical Cord, Adipose Tissue and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 III-42

Table 65: China Historic Review for Cell Harvesting by Application - Peripheral Blood, Bone Marrow, Umbilical Cord, Adipose Tissue and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 III-43

Table 66: China 15-Year Perspective for Cell Harvesting by Application - Percentage Breakdown of Value Sales for Peripheral Blood, Bone Marrow, Umbilical Cord, Adipose Tissue and Other Applications for the Years 2012, 2020 & 2027 III-44

Table 67: China Current & Future Analysis for Cell Harvesting by End-Use - Biotech & Biopharma Companies, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 III-45

Table 68: China Historic Review for Cell Harvesting by End-Use - Biotech & Biopharma Companies, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 III-46

Table 69: China 15-Year Perspective for Cell Harvesting by End-Use - Percentage Breakdown of Value Sales for Biotech & Biopharma Companies, Research Institutes and Other End-Uses for the Years 2012, 2020 & 2027 III-47

EUROPE III-48 Cancer in Europe: Key Statistics III-48 Exhibit 21: Cancer Incidence in Europe: Number of New Cancer Cases (in Thousands) by Site for 2018 III-48 Ageing Population to Drive Demand for Cell Harvesting Market III-49 Exhibit 22: European Population by Age Group (2016, 2030 & 2050): Percentage Share Breakdown by Age Group for 0-14, 15- 64, and 65 & Above III-49 Market Analytics III-50 Table 70: Europe Current & Future Analysis for Cell Harvesting by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 III-50

Table 71: Europe Historic Review for Cell Harvesting by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 III-51

Table 72: Europe 15-Year Perspective for Cell Harvesting by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2012, 2020 & 2027 III-52

Table 73: Europe Current & Future Analysis for Cell Harvesting by Type - Manual and Automated - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 III-53

Table 74: Europe Historic Review for Cell Harvesting by Type - Manual and Automated Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 III-54

Table 75: Europe 15-Year Perspective for Cell Harvesting by Type - Percentage Breakdown of Value Sales for Manual and Automated for the Years 2012, 2020 & 2027 III-55

Table 76: Europe Current & Future Analysis for Cell Harvesting by Application - Peripheral Blood, Bone Marrow, Umbilical Cord, Adipose Tissue and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 III-56

Table 77: Europe Historic Review for Cell Harvesting by Application - Peripheral Blood, Bone Marrow, Umbilical Cord, Adipose Tissue and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 III-57

Table 78: Europe 15-Year Perspective for Cell Harvesting by Application - Percentage Breakdown of Value Sales for Peripheral Blood, Bone Marrow, Umbilical Cord, Adipose Tissue and Other Applications for the Years 2012, 2020 & 2027 III-58

Table 79: Europe Current & Future Analysis for Cell Harvesting by End-Use - Biotech & Biopharma Companies, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 III-59

Table 80: Europe Historic Review for Cell Harvesting by End-Use - Biotech & Biopharma Companies, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 III-60

Table 81: Europe 15-Year Perspective for Cell Harvesting by End-Use - Percentage Breakdown of Value Sales for Biotech & Biopharma Companies, Research Institutes and Other End-Uses for the Years 2012, 2020 & 2027 III-61

FRANCE III-62 Table 82: France Current & Future Analysis for Cell Harvesting by Type - Manual and Automated - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 III-62

Table 83: France Historic Review for Cell Harvesting by Type - Manual and Automated Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 III-63

Table 84: France 15-Year Perspective for Cell Harvesting by Type - Percentage Breakdown of Value Sales for Manual and Automated for the Years 2012, 2020 & 2027 III-64

Table 85: France Current & Future Analysis for Cell Harvesting by Application - Peripheral Blood, Bone Marrow, Umbilical Cord, Adipose Tissue and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 III-65

Table 86: France Historic Review for Cell Harvesting by Application - Peripheral Blood, Bone Marrow, Umbilical Cord, Adipose Tissue and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 III-66

Table 87: France 15-Year Perspective for Cell Harvesting by Application - Percentage Breakdown of Value Sales for Peripheral Blood, Bone Marrow, Umbilical Cord, Adipose Tissue and Other Applications for the Years 2012, 2020 & 2027 III-67

Link:
Global Cell Harvesting Market to Reach US$381,4 Million by the Year 2027 - PRNewswire

DUBLIN, Nov. 25, 2020 /PRNewswire/ -- The "Global Biomaterials Market By Product (Implants, Valves, Joint Replacement, Contact Lenses and Others), By Material Type (Metallic, Natural, Ceramics, Polymeric, Living Cell and Tissue), By Type, By Application, By End User, By Region, Forecast & Opportunities, 2025" report has been added to ResearchAndMarkets.com's offering.

The Global Biomaterials Market is expected to register substantial rate of growth during the forecast period owing to factors like increasing geriatric population, rapidly growing healthcare sector and its wider use in various products and applications, such as contact lenses, skin repair, blood vessel prosthesis, gene transfer, drug delivery, and dental.

Biomaterials are artificially derived synthetic or natural materials which are used to interact with biological systems for medical purposes and treatments. They are often used in medical applications to augment or replace a natural function. The biomaterial market is anticipated to grow significantly during the next five years due to discoveries in tissue engineering, regenerative medicine, and more. They often are biodegradable, and some are bio-absorbable, meaning they are eliminated gradually from the body after fulfilling a function. Additionally, metals, ceramics, plastic, glass, and even living cells and tissue all can be used in creating a biomaterial. Moreover, heavy funding by government organizations for innovation of new products is creating new scope for the growth in biomaterials market. Rising prevalence of cardiovascular, neurological, & orthopedic disorders, coupled with increasing awareness regarding the advantages of biomaterials products is further driving the market. Furthermore, rising prevalence of cardiovascular, neurological, & orthopedic disorders around the world is anticipated to create major demand for biomaterials through 2025.

The Global Biomaterials Market is segmented based on product, material type, type, application, end-user, and region. Based on material type, the market is segmented into metallic, natural, ceramics, polymeric, living cell and tissue. The metallic biomaterials segment held lion's share in 2019 due to wide use of metals in the manufacturing of medical devices and their use in orthopedic procedures for bone support and replacement, as they are strong and resistant to fatigue degradation.

By region, North America dominates the biomaterials market owing to the initiatives undertaken by several public and private organizations in the region. Also, factors such as favorable government policies and presence of major market players made the region dominant in terms of revenue share in 2019. However, Asia-Pacific region is expected to register highest CAGR in the coming years due to a large population base in countries like India and China coupled with growing incidences of chronic diseases and rising awareness about biomaterials in the region.

Objective of the Study:

Key Topics Covered:

1. Product Overview

2. Research Methodology

3. Impact of COVID-19 on Global Biomaterials Market

4. Executive Summary

5. Global Biomaterials Market Outlook5.1. Market Size & Forecast5.1.1. By Value & Volume5.2. Market Share & Forecast5.2.1. By Product (Implants, Valves, Joint Replacement, Contact Lenses and Others)5.2.2. By Material Type (Metallic, Natural, Ceramics, Polymeric, Living Cell and Tissue)5.2.3. By Type (Bioinert, Bioresorbable, Bio Tolerant and Bioactive)5.2.4. By Application (Ophthalmology, Cardiovascular, Orthopedic, Wound Healing, Plastic Surgery, Neurology, Dental, Others)5.2.5. By End User (Private Hospitals, Government Hospitals, Specialty Clinics)5.2.6. By Company (2019)5.2.7. By Region5.3. Market Attractiveness Index

6. Asia-Pacific Biomaterials Market Outlook6.1. Market Size & Forecast6.1.1. By Value & Volume6.2. Market Share & Forecast6.2.1. By Material Type6.2.2. By Application6.2.3. By Country6.3. Market Attractiveness Index6.4. Asia-Pacific: Country Analysis6.4.1. China Biomaterials Market Outlook6.4.1.1. Market Size & Forecast6.4.1.1.1. By Value6.4.1.2. Market Share & Forecast6.4.1.2.1. By Material Type6.4.1.2.2. By Application6.4.2. India Biomaterials Market Outlook6.4.2.1. Market Size & Forecast6.4.2.1.1. By Value6.4.2.2. Market Share & Forecast6.4.2.2.1. By Material Type6.4.2.2.2. By Application6.4.3. Japan Biomaterials Market Outlook6.4.3.1. Market Size & Forecast6.4.3.1.1. By Value6.4.3.2. Market Share & Forecast6.4.3.2.1. By Material Type6.4.3.2.2. By Application6.4.4. South Korea Biomaterials Market Outlook6.4.4.1. Market Size & Forecast6.4.4.1.1. By Value6.4.4.2. Market Share & Forecast6.4.4.2.1. By Material Type6.4.4.2.2. By Application6.4.5. Singapore Biomaterials Market Outlook6.4.5.1. Market Size & Forecast6.4.5.1.1. By Value6.4.5.2. Market Share & Forecast6.4.5.2.1. By Material Type6.4.5.2.2. By Application6.4.6. Australia Biomaterials Market Outlook6.4.6.1. Market Size & Forecast6.4.6.1.1. By Value6.4.6.2. Market Share & Forecast6.4.6.2.1. By Material Type6.4.6.2.2. By Application

7. Europe Biomaterials Market Outlook7.1. Market Size & Forecast7.1.1. By Value & Volume7.2. Market Share & Forecast7.2.1. By Material Type7.2.2. By Application7.2.3. By Country7.3. Market Attractiveness Index7.4. Europe: Country Analysis7.4.1. France Biomaterials Market Outlook7.4.1.1. Market Size & Forecast7.4.1.1.1. By Value7.4.1.2. Market Share & Forecast7.4.1.2.1. By Material Type7.4.1.2.2. By Application7.4.2. Germany Biomaterials Market Outlook7.4.2.1. Market Size & Forecast7.4.2.1.1. By Value7.4.2.2. Market Share & Forecast7.4.2.2.1. By Material Type7.4.2.2.2. By Application7.4.3. United Kingdom Biomaterials Market Outlook7.4.3.1. Market Size & Forecast7.4.3.1.1. By Value7.4.3.2. Market Share & Forecast7.4.3.2.1. By Material Type7.4.3.2.2. By Application7.4.4. Italy Biomaterials Market Outlook7.4.4.1. Market Size & Forecast7.4.4.1.1. By Value7.4.4.2. Market Share & Forecast7.4.4.2.1. By Material Type7.4.4.2.2. By Application7.4.4.2.3. By End User

8. North America Biomaterials Market Outlook8.1. Market Size & Forecast8.1.1. By Value & Volume8.2. Market Share & Forecast8.2.1. By Material Type8.2.2. By Application8.2.3. By Country8.3. Market Attractiveness Index8.4. North America: Country Analysis8.4.1. United States Biomaterials Market Outlook8.4.1.1. Market Size & Forecast8.4.1.1.1. By Value8.4.1.2. Market Share & Forecast8.4.1.2.1. By Material Type8.4.1.2.2. By Application8.4.2. Mexico Biomaterials Market Outlook8.4.2.1. Market Size & Forecast8.4.2.1.1. By Value8.4.2.2. Market Share & Forecast8.4.2.2.1. By Material Type8.4.2.2.2. By Application8.4.3. Canada Biomaterials Market Outlook8.4.3.1. Market Size & Forecast8.4.3.1.1. By Value8.4.3.2. Market Share & Forecast8.4.3.2.1. By Material Type8.4.3.2.2. By Application

9. South America Biomaterials Market Outlook9.1. Market Size & Forecast9.1.1. By Value & Volume9.2. Market Share & Forecast9.2.1. By Material Type9.2.2. By Application9.2.3. By Country9.3. Market Attractiveness Index9.4. South America: Country Analysis9.4.1. Brazil Biomaterials Market Outlook9.4.1.1. Market Size & Forecast9.4.1.1.1. By Value9.4.1.2. Market Share & Forecast9.4.1.2.1. By Material Type9.4.1.2.2. By Application9.4.2. Argentina Biomaterials Market Outlook9.4.2.1. Market Size & Forecast9.4.2.1.1. By Value9.4.2.2. Market Share & Forecast9.4.2.2.1. By Material Type9.4.2.2.2. By Application9.4.3. Colombia Biomaterials Market Outlook9.4.3.1. Market Size & Forecast9.4.3.1.1. By Value9.4.3.2. Market Share & Forecast9.4.3.2.1. By Material Type9.4.3.2.2. By Application

10. Middle East and Africa Biomaterials Market Outlook10.1. Market Size & Forecast10.1.1. By Value & Volume10.2. Market Share & Forecast10.2.1. By Material Type10.2.2. By Application10.2.3. By Country10.3. Market Attractiveness Index10.4. MEA: Country Analysis10.4.1. South Africa Biomaterials Market Outlook10.4.1.1. Market Size & Forecast10.4.1.1.1. By Value10.4.1.2. Market Share & Forecast10.4.1.2.1. By Material Type10.4.1.2.2. By Application10.4.2. Saudi Arabia Biomaterials Market Outlook10.4.2.1. Market Size & Forecast10.4.2.1.1. By Value10.4.2.2. Market Share & Forecast10.4.2.2.1. By Material Type10.4.2.2.2. By Application10.4.3. UAE Biomaterials Market Outlook10.4.3.1. Market Size & Forecast10.4.3.1.1. By Value10.4.3.2. Market Share & Forecast10.4.3.2.1. By Material Type10.4.3.2.2. By Application

11. Market Dynamics11.1. Drivers11.2. Challenges

12. Market Trends & Developments

13. Competitive Landscape13.1. Competition Outlook13.2. Players Profiled (Leading Companies)13.2.1. Koninklijke DSM N.V.13.2.2. Bayer AG13.2.3. Corbion NV13.2.4. Wright Medical Technology, Inc.13.2.5. Zimmer Biomet Holdings, Inc.13.2.6. Collagen Matrix, Inc.13.2.7. Noble Biomaterials Inc13.2.8. Covalon Technologies Ltd13.2.9. Olympus corporation13.2.10. Johnson & Johnson13.2.11. Cook Medical13.2.12. Smith and Nephew13.2.13. Becton Dickinson13.2.14. Medtronic13.2.15. Angiodynamics

14. Strategic Recommendations

15. About Us & Disclaimer

For more information about this report visit https://www.researchandmarkets.com/r/j7yiqc

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets Laura Wood, Senior Manager [emailprotected]

For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets

http://www.researchandmarkets.com

See more here:
Insights on the Biomaterials Global Market to 2025 - Forecast and Opportunities - PRNewswire

CAMBRIDGE, Mass.--(BUSINESS WIRE)--ElevateBio, LLC, a Cambridge-based creator and operator of a portfolio of innovative cell and gene therapy companies, will present at the Piper Sandler 32nd Annual Virtual Healthcare Conference on November 30, 2020.

The presentations will be available for registered attendees via the Piper Sandler conference site from November 23 to December 3 and will also be available on the Investors & Media section of the ElevateBio website at https://www.elevate.bio/investors-and-media. An archived replay of the presentation will be available for approximately 30 days following the presentation.

About ElevateBio

ElevateBio, LLC, is a Cambridge-based creator and operator of a portfolio of innovative cell and gene therapy companies. It begins with an environment where scientific inventors can transform their visions for cell and gene therapies into reality for patients with devastating and life-threatening diseases. Working with leading academic researchers, medical centers, and corporate partners, ElevateBios team of scientists, drug developers, and company builders are creating a portfolio of therapeutics companies that are changing the face of cell and gene therapy and regenerative medicine. Core to ElevateBios vision is BaseCamp, a centralized state-of-the-art innovation and manufacturing center, providing fully integrated capabilities, including basic and transitional research, process development, clinical development, cGMP manufacturing, and regulatory affairs across multiple cell and gene therapy and regenerative medicine technology platforms. ElevateBio portfolio companies, as well as select strategic partners are supported by ElevateBio BaseCamp in the advancement of novel cell and gene therapies.

ElevateBios investors include F2 Ventures, MPM Capital, EcoR1 Capital, Redmile Group, Samsara BioCapital, The Invus Group, Surveyor Capital (A Citadel company), EDBI, and Vertex Ventures HC.

ElevateBio is headquartered in Cambridge, Mass, with ElevateBio BaseCamp located in Waltham, Mass. For more information, please visit http://www.elevate.bio.

Link:
ElevateBio to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference - Business Wire

Good lifestyle choices exercising regularly, eating a healthy diet, not smoking, and drinking in moderation obviously makes a big difference in staying healthy. Research in the last few decades has shown, however, that environmental exposures may also contribute to major diseases and health problems that disproportionately affect men, including heart disease, prostate cancer, infertility, and skin cancer.

These exposures involve a number of toxic substances that turn up in food, food packaging, drinking water, and personal care products. Fortunately, there are simple steps men can take to significantly lower their risks.

For example, risk factors for heart disease have been linked to mercury from certain seafoods, Teflon chemicals in non-stick cookware, bisphenol-A (BPA) in hard plastic containers, and canned foods, as well as the arsenic and lead in much of the nations drinking water.

Similarly, prostate cell damage has been traced to the plastics chemical BPA and the heavy metal cadmium. Increased prostate cancer risk has been associated with certain agricultural pesticides common on some fruits and vegetables and polychlorinated biphenyls (PCBs) that build up in meat and dairy products.

And while many people mistakenly think of infertility as primarily a womans problem, the fact is that in about 40% of infertile couples, its the male who is either the sole or a contributing source of the problem. Several studies have tied sperm deficiency to a variety of environmental factors, including exposures to lead, chemicals in personal care products, and pesticides.

Skin cancer is also an especially important issue for men, who are at a higher risk than women of developing and dying from melanoma, the deadliest form.

While many believe that theres not much a man can do about his genetics, this is a common misconception. In fact, many interventions exist that will fix a mans genetic makeup. That is because its not always about what genes you have, but its about what genes are turned on and which ones are turned off.

A huge reason why you will feel better is that you will be turning on good genes and turning off bad genes. This is called epigenetics, which is why you will start feeling so much better. By reversing your current health problems and preventing new ones from starting, you will be empowered to thrive with a healthier lifestyle.

Aside from genetics, there are lots of ways to reduce potentially harmful environmental exposures. Here are five steps you can take immediately:

Invest in the right in-home water filter system to reduce your exposure to lead, arsenic, and other drinking water contaminants.

2. Spot and Avoid Products with BPA

Avoid canned foods and plastic containers with the recycling code No. 7 to lower your exposure to BPA dramatically.

At the supermarket, choose the conventionally grown fruits and vegetables that have the fewest pesticide residues and buy organic versions of those.

4. Know the Grooming Ingredients

When buying deodorant, soap, lotions, and shampoos, consult http://www.EWG.org/skindeep which is an extensive database of nearly 80,000 personal care products to highlight those products that are free of toxic chemicals.

Learn more about skin cancer and melanoma, use proper sun protection, and get regular skin checks with a dermatologist.

Liberally apply sunscreen about 20 to 30 minutes before going outside. And dont forget your ears, scalp, back of neck, and the tops of your feet. Some of the worse burns occur there. Because the sun emits two types of harmful rays UVA and UVB your sunscreen should provide broad-spectrum protection against both.

The specialists at Bingham Healthcare Dermatology highly recommend using sunscreen with an SPF of 30 or greater with the physical UV blockers zinc oxide. (Avoid sunscreens that contain titanium dioxide as studies have shown this could lead to decreased testosterone levels.)

About David J. Bilstrom, MD

Dr. Bilstrom is director of the International Autoimmune Institute & Bingham Memorial Center for Functional Medicine, which is the first medical center in the country to treat all types of autoimmune diseases. It is also the first to use nature, and its ability to improve human health and well-being, as an integral part of a wellness program.

He is quadruple board certified in Functional and Regenerative Medicine, Integrative Medicine, Physical Medicine and Rehabilitation, and Medical Acupuncture. He has extensive experience in Anti-Aging & Regenerative Medicine, Acupuncture, Integrative Medicine, and Complementary and Alternative Medicines.

Dr. Bilstrom works closely with experts in a number of medical specialties to evaluate, diagnose and treat chronic and autoimmune diseases. He is always welcoming new patients at his office within the Bingham Specialty Plaza in Blackfoot. Appointments can be scheduled by calling (208) 782-2444.

Bingham Memorial Specialty Clinic

More:
Toxins, the environment, and your health - Post Register

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the permanent loss of capital.' So it might be obvious that you need to consider debt, when you think about how risky any given stock is, because too much debt can sink a company. We can see that China Regenerative Medicine International Limited (HKG:8158) does use debt in its business. But the more important question is: how much risk is that debt creating?

Generally speaking, debt only becomes a real problem when a company can't easily pay it off, either by raising capital or with its own cash flow. If things get really bad, the lenders can take control of the business. However, a more frequent (but still costly) occurrence is where a company must issue shares at bargain-basement prices, permanently diluting shareholders, just to shore up its balance sheet. Of course, debt can be an important tool in businesses, particularly capital heavy businesses. The first step when considering a company's debt levels is to consider its cash and debt together.

View our latest analysis for China Regenerative Medicine International

You can click the graphic below for the historical numbers, but it shows that China Regenerative Medicine International had HK$220.2m of debt in June 2020, down from HK$282.4m, one year before. However, it also had HK$32.4m in cash, and so its net debt is HK$187.8m.

Zooming in on the latest balance sheet data, we can see that China Regenerative Medicine International had liabilities of HK$311.5m due within 12 months and liabilities of HK$163.5m due beyond that. On the other hand, it had cash of HK$32.4m and HK$253.0m worth of receivables due within a year. So it has liabilities totalling HK$189.5m more than its cash and near-term receivables, combined.

Given China Regenerative Medicine International has a market capitalization of HK$1.17b, it's hard to believe these liabilities pose much threat. However, we do think it is worth keeping an eye on its balance sheet strength, as it may change over time. There's no doubt that we learn most about debt from the balance sheet. But it is China Regenerative Medicine International's earnings that will influence how the balance sheet holds up in the future. So if you're keen to discover more about its earnings, it might be worth checking out this graph of its long term earnings trend.

In the last year China Regenerative Medicine International wasn't profitable at an EBIT level, but managed to grow its revenue by 358%, to HK$154m. When it comes to revenue growth, that's like nailing the game winning 3-pointer!

Despite the top line growth, China Regenerative Medicine International still had an earnings before interest and tax (EBIT) loss over the last year. Its EBIT loss was a whopping HK$239m. Considering that alongside the liabilities mentioned above does not give us much confidence that company should be using so much debt. Quite frankly we think the balance sheet is far from match-fit, although it could be improved with time. Another cause for caution is that is bled HK$324m in negative free cash flow over the last twelve months. So suffice it to say we consider the stock very risky. The balance sheet is clearly the area to focus on when you are analysing debt. However, not all investment risk resides within the balance sheet - far from it. Be aware that China Regenerative Medicine International is showing 4 warning signs in our investment analysis , and 3 of those shouldn't be ignored...

If you're interested in investing in businesses that can grow profits without the burden of debt, then check out this free list of growing businesses that have net cash on the balance sheet.

PromotedIf youre looking to trade China Regenerative Medicine International, open an account with the lowest-cost* platform trusted by professionals, Interactive Brokers. Their clients from over 200 countries and territories trade stocks, options, futures, forex, bonds and funds worldwide from a single integrated account.

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. *Interactive Brokers Rated Lowest Cost Broker by StockBrokers.com Annual Online Review 2020

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com.

Original post:
Does China Regenerative Medicine International (HKG:8158) Have A Healthy Balance Sheet? - Simply Wall St

New York, Nov. 25, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "North America Artificial Joints Market Forecast to 2027 - COVID-19 Impact and Regional Analysis By Type ; Material ; Application ; End User and Country" - https://www.reportlinker.com/p05989565/?utm_source=GNW North America Artificial Joints market is expected to grow due to factors such as to increasing prevalence of bone and joint conditions, increasing prevalence of obesity, and rising government support by introducing guidelines for regenerative medicines. However, high cost and complications associated with the artificial joint surgery is expected to hinder market growth.

An artificial joint is a device used in orthopedic surgery procedures in which an arthritic or dysfunctional joint surface is surgically replaced.Extensively increasing geriatric population coupled with sedentary lifestyle are the most prevalent conditions for the growth of bone and joint diseases worldwide.

According to a data published by CDC (Centers for Disease Control and Prevention) in 2020, an estimated 32.5 million Americans are suffering from osteoarthritis. Such massive prevalence of bone and joint defects are estimated to have positive impact on the demand of bone replacement procedures, which will eventually drive the market growth during the forecast period. Also, a rising number of sports injuries among athletes is also anticipated to have an impact on the growth of the market by certain extent.

However, due to the negative impact of COVID-19, health care systems are overburdened, and the medical care delivery to all patients has become a challenge in North America. The complete shutdown of businesses offering artificial joints in the United States and several other areas will cause the regions supply chain disruptions.

Based on Product, the North America Artificial Joints market is segmented into cemented joints and non-cemented joints. The cemented joints segment held the largest share of the market in 2019 and is expected to register the highest CAGR in the market during the forecast period.

The North America Artificial Joints market, by material, is segmented into ceramics, alloys, oxinium, others. The ceramic segment held the largest share of the market in 2019, however, alloys segment is anticipated to register the highest CAGR in the market during the forecast period.

Based on Application, the North America Artificial Joints market is segmented into artificial joints of knee, artificial joints of hip, artificial joints of shoulder, others. The artificial joints of knee segment held the largest share of the market in 2019 and is expected to register the highest CAGR in the market during the forecast period.

The North America Artificial Joints market, based on end user, is segmented into artificial joints of hospitals, ambulatory care centers, and other end users. The hospital segment held the largest share of the market in 2019 and is anticipated to register the highest CAGR in the market during the forecast period.

A few of the major primary and secondary sources associated with this report on the North America Artificial Joints market are the US Food and Drug Administration (FDA), International Society of Arthroplasty, Knee Surgery and Orthopedic Sports Medicine (ISAKOS), World Health Organization (WHO) and National Health Service (NHS).Read the full report: https://www.reportlinker.com/p05989565/?utm_source=GNW

About ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

Original post:
North America Artificial Joints Market Forecast to 2027 - COVID-19 Impact and Regional Analysis By Type ; Material ; Application ; End User and...

London, Nov. 25, 2020 (GLOBE NEWSWIRE) -- According to a new market research report Collagen Market by Product (Gelatin, Collagen Peptide, Native Collagen, Synthetic Collagen), Source (Porcine, Bovine, Chicken, Sheep, Other Sources), and Application (Food and Beverages, Pharmaceuticals, Nutraceuticals, Cosmetics, Healthcare) - Global Forecasts to 2027, published by Meticulous Research, in terms of value, the collagen market is expected to grow at a CAGR of 6.9% to reach $7.53 billion by 2027; while in terms of volume, the market is expected to grow at a CAGR of 5.1% to reach 683.8 KT by 2027.

DownloadFree Sample Report Now @ https://www.meticulousresearch.com/download-sample-report/cp_id=5121

The overall collagen market is primarily driven by its growing use in the food industry, growing demand for protein consumption and nutricosmetics, increasing application in healthcare, and growing use of collagen-based biomaterials. In addition, rise in per capita income and booming food processing industry is providing significant opportunities to collagen manufacturers all across the globes. But, safety concerns and improvement in the processing technology are still a challenge for this market. Therefore, safety concerns, religious constraints, and growing use of alternatives are expected to restrain the growth of this market to some extent.

The global collagen market is mainly segmented by type (gelatin, collagen peptide, native collagen, synthetic collagen), source (bovine, porcine, marine, chicken, sheep, and other sources), application (food and beverages, pharmaceuticals, nutraceuticals, healthcare, cosmetics, and technical applications), and geography.

Speak to our Analysts to Understand the Impact of COVID-19 on Your Business:https://www.meticulousresearch.com/speak-to-analyst/cp_id=5121

Based on type, the overall collagen market is mainly segmented into gelatin, collagen peptide, native collagen, and synthetic collagen. Gelatin segment is estimated to account for the largest share of the overall collagen market in 2020. The large share of this segment is mainly attributed to the increased demand from the food and pharmaceutical industries, owing to its outstanding stabilizing features and binding characteristics. The nutritional gummies, chewable soft capsules, and enteric capsules are the recent trends in the pharma drug deliveries where mass volume of gelatin is being used. In addition, growing usage of gelatin in photography, nutraceuticals, and cosmeceuticals are also contributing to its large adoption.

Based on source, the overall collagen market is segmented into bovine, porcine, fish, chicken, sheep, and other sources. The bovine collagen segment is estimated to command the largest share of the overall collagen market in 2020. The large share of this segment is mainly attributed to the growing beef consumption and its several health benefits such as skin health, tendon reinforcement, bone loss prevention, and relief from arthritis. However, fish collagen segment is expected to grow at the fastest CAGR during the forecast period. The rapid growth of this segment is mainly attributed to the rising fish production and growing cosmetic industry across the globe.

Based on application, the overall collagen market is mainly segmented into food and beverages, pharmaceuticals, nutraceuticals, healthcare, cosmetics, and technical applications. The food and beverages segment is estimated to command the largest share of the overall collagen market in 2020, mainly attributed to vast applications of collagen across the food and beverages industry due to its unique gelling and surface behavior properties. However, nutraceuticals segment is expected to grow at the highest CAGR during the forecast period. The rapid growth of this segment is mainly attributed to the growing use of nutraceuticals for weight management across the globe.

Quick Buy Collagen Market Research Report: https://www.meticulousresearch.com/buy_now.php?pformat=425&vformat=1261

The global collagen market is divided into six major regions, namely North America, Europe, Asia-Pacific, Latin America, Africa, and the Middle East. The North America region accounted for the largest share of the global collagen market in 2020. The largest share of this region is mainly attributed to the huge consumption of cosmeceuticals and nutraceuticals, rise in research and development activities, well established food and healthcare industry, and easy availability of raw materials. However, the Asia-Pacific region is expected to grow at the highest CAGR during the forecast period. The fast growth of the region is mainly due to the increasing number of food manufacturers and the prevailing food processing industry particularly in China and India; growing population; rising awareness of nutrition and personal well-being; steady pace of industrialization; high spending on personal care products; and abundant availability of raw material for collagen and gelatin manufacturing.

The key players operating in the global collagen market are Rousselot (The Netherlands), GELITA AG (Germany), Weishardt (France), Tessenderlo Group NV (Belgium), Nitta Gelatin Inc. (Japan), LAPI GELATINE S.p.a. (Italy), ITALGELATINE S.p.A. (Italy), Ewald-Gelatine GmbH (Germany), REINERT GRUPPE Ingredients GmbH (Germany), Trobas Gelatine B.V. (The Netherlands), GELNEX (Brazil), Junc Gelatines SL (Spain), HolistaCollTech Ltd. (Australia), Collagen Solutions Plc. (U.K.), and Advanced BioMatrix, Inc. (U.S.).

To gain more insights into the market with a detailed table of content and figures, click here:https://www.meticulousresearch.com/product/collagen-market-5121/

Scope of the report

Collagen Market, by Type

Collagen Market, by Source

Collagen Market, by Application

Collagen Market, by Geography

DownloadFree Sample Report Now @https://www.meticulousresearch.com/download-sample-report/cp_id=5121

Amidst this crisis, Meticulous Researchis continuously assessing the impact of COVID-19 pandemic on various sub-markets and enables global organizations to strategize for the post-COVID-19 world and sustain their growth. Let us know if you would like to assess the impact of COVID-19 on any industry here-https://www.meticulousresearch.com/custom-research.php

Related Reports:

Artificial Casings Market by Type (Collagen Casing, Cellulose Casing, Plastic Casing, Fibrous Casing, Value Added Casing, Textile Casing, and Net Casing) and GeographyGlobal Forecast to 2025

https://www.meticulousresearch.com/product/artificial-casings-market-5035/

South East Asian Collagen Market by Product (Collagen Peptide and Gelatin), Source (Porcine, Bovine, Marine, Chicken, Sheep, and Other Animals), Application (Food and Beverages, Cosmetics, Nutraceuticals, Pharmaceuticals, Healthcare, and Technical) Industry Forecast to 2023

https://www.meticulousresearch.com/product/south-east-asia-collagen-market-2023/

Collagen and Gelatin Market for Regenerative Medicine by Type, (Collagen and Gelatin), by Source, (Bovine, Porcine, Marine, and others), by Application, (Orthopedic, Wound Care, Cardiovascular, and others) - Global Forecast to 2022

https://www.meticulousresearch.com/product/collagen-gelatin-market-regenerative-medicine-2022/

About Meticulous Research

Meticulous Research was founded in 2010 and incorporated as Meticulous Market Research Pvt. Ltd. in 2013 as a private limited company under the Companies Act, 1956. Since its incorporation, the company has become the leading provider of premium market intelligence in North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa.

The name of our company defines our services, strengths, and values. Since the inception, we have only thrived to research, analyze and present the critical market data with great attention to detail. With meticulous primary and secondary research techniques, we have built strong capabilities in data collection, interpretation, and analysis of data including qualitative and quantitative research with the finest team of analysts. We design our meticulously analyzed intelligent and value-driven syndicate market research reports, custom studies, quick turnaround research, and consulting solutions to address business challenges of sustainable growth.

Contact:Mr. Khushal BombeMeticulous ResearchDirect Lines: +1-646-781-8004 (North America)+44-203-868-8738 (Europe)+91 744-7780008 (Asia-Pacific)Email- sales@meticulousresearch.comVisit Our Website: https://www.meticulousresearch.com/Connect with us on LinkedIn- https://www.linkedin.com/company/meticulous-researchContent Source: https://www.meticulousresearch.com/press-release/collagen-market-2027/479/

Visit link:
Collagen Market Worth $7.53 billion by 2027- Exclusive Report Covering Pre and Post COVID-19 Market Analysis by Meticulous Research - GlobeNewswire

NEW YORK & CARLSBAD, Calif.--(BUSINESS WIRE)--Biotech Showcase Digital is the investor conference that drives the future of biotech innovation, digital medicine, and international collaboration. In its 13th year, the conference will be a virtual experience for attendees in an engaging, live and on-demand format delivered through partneringONE between January 1115, 2021. For the first time ever, content and presentations will be released beginning November 30, 2020. Register today to begin scheduling meetings with potential investors and partners.

In just the past five years, 250 companies that presented at Biotech Showcase have generated deals worth more than $61 Billion. The organizers anticipate more than 300 public and private presenting companies this year. A full list of currently registered presenting companies can be found here. More generally, noteworthy conference participants and sponsors include Ajinomoto, Alliance for Regenerative Medicine, Bayer, Global Genes, Novo Nordisk, Silicon Valley Bank and Startup Health.

"One of the industry's largest annual healthcare investor and partnering conferences, Biotech Showcase brings together biopharma and life sciences thought leaders who set the tone and pace for the coming year in biotech," said Tomas Landh, Innovation Sourcing Vice President, Senior Principal Scientist Search and Evaluation at Novo Nordisk. "Every year, our team looks forward to participating in meetings with our existing and potential partners during Biotech Showcase. 2021 will be no different other than the fact that the experience will be delivered in an innovative digital platform."

To make the experience as valuable and seamless as possible, Biotech Showcase offers:

According to Sara Jane Demy, Founder and CEO, Demy-Colton, As we continue navigating these unprecedented times and prepare for the promise of a new year, staying connected within the life sciences industry is more important than ever. In its virtual form, Biotech Showcase will continue to be a place to create a link between investors and the industrys most promising biotech and pharmaceutical companies.

Tina Gunnink, Managing Director, EBD Group US, added Biotech Showcase remains one of the largest investor conferences for the life sciences most innovative companies and is a particularly pivotal touchpoint for those looking for partnerships and investment. We are looking forward to seeing the continued collaboration for Biotech Showcase 2021.

Organizers anticipate more than 2,500 virtual attendees this year and have designed a program to provide them with industry updates and insights from leading executives and advisors as well as key sessions. Conference registration also gives attendees access to the Biotech Showcase program as well as its sister events Digital Medicine & Medtech Showcase and Seed Showcase.

For more information or to register for the event, visit http://www.biotechshowcase.com.

About Demy-Colton

Since 2008, Demy-Colton has been at the forefront of building networks between leaders from innovative biotech companies and industry stakeholders to examine and address biotech opportunities and challenges and deliver on the promise of transformational science.

Demy-Colton achieves this with unique meeting platforms that facilitate networking and biotech community development on an international scale. Aside from Biotech Showcase, its investor and specialized events include BioFuture, CEO Summit Europe, and CEO Summit Napa, Demy-Colton Virtual Salons, and CEO Virtual Dialogues. Its events build networking communities that transcend geographical boundaries and establish ongoing, high-value relationships among the industrys top decision makers, investors, and thought leaders.

Demy-Colton sets a unique stage where investment, learning, and growth thrive. Its events spur introductions and thoughtful conversations. In turn, inspiration, ideas, and opportunities for investment flow.

About EBD Group

EBD Groups overriding mission is to help collaborations get started across the life sciences value chain. Our range of partnering conferences has grown to become the largest and most productive conference platform in the industry. Each one of our landmark events held in key life sciences markets around the world is powered by our state-of-the-art partnering software, partneringONE, that enables delegates to efficiently identify and engage with new opportunities via one-to-one meetings.

Today our events (BIO-Europe, BIO-Europe Spring, BioPharm America, Biotech Showcase, China Showcase, Digital Medicine & Medtech Showcase, ChinaBio Partnering Forum, Rare Disease Innovation and Partnering Summit, and BioEquity Europe) annually attract more than 15,000 senior life sciences executives who engage in over 50,000 one-to-one partnering meetings. These vital one-to-one engagements are the wellspring of deals that drive innovation in our industry.

Read more:
13th Annual Biotech Showcase to Bring Together Attendees Digitally in 2021 for Investing, Partnering and Collaboration - Business Wire

Global Regenerative Medicine Products Market Research Report 2020

The Lexis Business Insights added a new report Global Regenerative Medicine Products Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2016 2024 in its database, which provides an expert and in-depth analysis of key business trends and future market development prospects, key drivers and restraints, profiles of major market players, segmentation and forecasting.

In 2020, the global Regenerative Medicine Products Market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2020-2025.

The global Regenerative Medicine Products Market report offers a complete overview of the Regenerative Medicine Products Market globally. It presents real data and statistics on the inclinations and improvements in global Regenerative Medicine Products Markets. It also highlights manufacturing, abilities & technologies, and unstable structure of the market. The global Regenerative Medicine Products Market report elaborates the crucial data along with all important insights related to the current market status.

The report additionally provides a pest analysis of all five along with the SWOT analysis for all companies profiled in the report. The report also consists of various company profiles and their key players; it also includes the competitive scenario, opportunities, and market of geographic regions. The regional outlook on the Regenerative Medicine Products market covers areas such as Europe, Asia, China, India, North America, and the rest of the globe.

Note In order to provide more accurate market forecast, all our reports will be updated before delivery by considering the impact of COVID-19.

Get sample copy of thisreport @ https://www.lexisbusinessinsights.com/request-sample-142529

Top key players @ Acelity, DePuy Synthes, Medtronic, ZimmerBiomet, Stryker, MiMedx Group, Organogenesis, UniQure, Cellular Dynamics International, Osiris Therapeutics, Vcanbio, Gamida Cell, Golden Meditech, Cytori Therapeutics, Celgene, Vericel Corporation, Guanhao Biotech, Mesoblast, Stemcell Technologes, and Bellicum Pharmaceuticals

The main goal for the dissemination of this information is to give a descriptive analysis of how the trends could potentially affect the upcoming future of Regenerative Medicine Products market during the forecast period. This markets competitive manufactures and the upcoming manufactures are studied with their detailed research. Revenue, production, price, market share of these players is mentioned with precise information.

Global Regenerative Medicine Products Market: Regional Segment Analysis

This report provides pinpoint analysis for changing competitive dynamics. It offers a forward-looking perspective on different factors driving or limiting market growth. It provides a five-year forecast assessed on the basis of how they Regenerative Medicine Products Market is predicted to grow. It helps in understanding the key product segments and their future and helps in making informed business decisions by having complete insights of market and by making in-depth analysis of market segments.

Key questions answered in the report include:

What will the market size and the growth rate be in 2026?

What are the key factors driving the Global Regenerative Medicine Products Market?

What are the key market trends impacting the growth of the Global Regenerative Medicine Products Market?

What are the challenges to market growth?

Who are the key vendors in the Global Regenerative Medicine Products Market?

What are the market opportunities and threats faced by the vendors in the Global Regenerative Medicine Products Market?

Trending factors influencing the market shares of the Americas, APAC, Europe, and MEA.

The report includes six parts, dealing with:

1.) Basic information;

2.) The Asia Regenerative Medicine Products Market;

3.) The North American Regenerative Medicine Products Market;

4.) The European Regenerative Medicine Products Market;

5.) Market entry and investment feasibility;

6.) The report conclusion.

Market Dynamics

The report analyzes the factors impacting the growth and the current market trends influencing the global Regenerative Medicine Products market. Detailed pricing information with ex-factory prices of various products by key manufacturers form a crucial part of the report. Competition analysis, along with regional government policies affecting the Regenerative Medicine Products market provides a detailed overview of the current status and prospects of the market. The impact of the ever-growing global population, coupled with technological advancements affecting the global Regenerative Medicine Products market is also covered in the report.

Drivers & Constraints

The report provides extensive information about the factors driving the global Regenerative Medicine Products market. Factors influencing the growth of the Regenerative Medicine Products market, along with technological advancements, are discussed extensively in the report. The current restraints of the market, limiting the growth and their future impact are also analyzed in the report. The report also discusses the impact of rising consumer demand, along with global economic growth on the Regenerative Medicine Products market.

Reasons for Buying this Report

This report provides pin-point analysis for changing competitive dynamics

It provides a forward looking perspective on different factors driving or restraining market growth

It provides a six-year forecast assessed on the basis of how the market is predicted to grow

It helps in understanding the key product segments and their future

It provides pin point analysis of changing competition dynamics and keeps you ahead of competitors

It helps in making informed business decisions by having complete insights of market and by making in-depth analysis of market segments

TABLE OF CONTENT:

1 Report Overview

2 Global Growth Trends

3 Market Share by Key Players

4 Breakdown Data by Type and Application

5 United States

6 Europe

7 China

8 Japan

9 Southeast Asia

10 India

11 Central & South America

12 International Players Profiles

13 Market Forecast 2019-2025

14 Analysts Viewpoints/Conclusions

15 Appendix

Get Up to 20% Discount on this Premium Report @

https://www.lexisbusinessinsights.com/request-sample-142529

If you have any special requirements, please let us know and we will offer you the report as you want.

About Us:

Statistical surveying reports are a solitary goal for all the business, organization and nation reports. We highlight huge archive of most recent industry reports, driving and specialty organization profiles, and market measurements discharged by rumored private distributors and open associations. Statistical surveying Store is the far reaching gathering of market knowledge items and administrations accessible on air. We have statistical surveying reports from number of driving distributors and update our gathering day by day to furnish our customers with the moment online access to our database. With access to this database, our customers will have the option to profit by master bits of knowledge on worldwide businesses, items, and market patterns

Contact Us:

Lexis Business Insights

Aaryan

(Director- Business Development)

US: +1 210 907 4145

6851 N Loop

1604 W San Antonio,

TX 78249

[emailprotected]

http://www.lexisbusinessinsights.com

Visit link:
Global Regenerative Medicine Products Market Size, Comprehensive Analysis, Development Strategy, Future Plans and Industry Growth with High CAGR by...

Regenerative medicine is a part of translational research in the fields of molecular biology and tissue engineering. This type of medicine involves replacing and regenerating human cells, organs, and tissues with the help of specific processes. Doing this may involve a partial or complete reengineering of human cells so that they start to function normally.

Get Exclusive PDF Sample Copy Of This Report:https://www.tmrresearch.com/sample/sample?flag=B&rep_id=1889

Regenerative medicine also involves the attempts to grow tissues and organs in a laboratory environment, wherein they can be put in a body that cannot heal a particular part. Such implants are mainly preferred to be derived from the patients own tissues and cells, particularly stem cells. Looking at the promising nature of stem cells to heal and regenerative various parts of the body, this field is certainly expected to see a bright future. Doing this can help avoid opting for organ donation, thus saving costs. Some healthcare centers might showcase a shortage of organ donations, and this is where tissues regenerated using patients own cells are highly helpful.

There are several source materials from which regeneration can be facilitated. Extracellular matrix materials are commonly used source substances all over the globe. They are mainly used for reconstructive surgery, chronic wound healing, and orthopedic surgeries. In recent times, these materials have also been used in heart surgeries, specifically aimed at repairing damaged portions.

Cells derived from the umbilical cord also have the potential to be used as source material for bringing about regeneration in a patient. A vast research has also been conducted in this context. Treatment of diabetes, organ failure, and other chronic diseases is highly possible by using cord blood cells. Apart from these cells, Whartons jelly and cord lining have also been shortlisted as possible sources for mesenchymal stem cells. Extensive research has conducted to study how these cells can be used to treat lung diseases, lung injury, leukemia, liver diseases, diabetes, and immunity-based disorders, among others.

Buy This Report @https://www.tmrresearch.com/checkout?rep_id=1889<ype=S

Global Regenerative Medicine Market: Overview

The global market for regenerative medicine market is expected to grow at a significant pace throughout the forecast period. The rising preference of patients for personalized medicines and the advancements in technology are estimated to accelerate the growth of the global regenerative medicine market in the next few years. As a result, this market is likely to witness a healthy growth and attract a large number of players in the next few years. The development of novel regenerative medicine is estimated to benefit the key players and supplement the markets growth in the near future.

Global Regenerative Medicine Market: Key Trends

The rising prevalence of chronic diseases and the rising focus on cell therapy products are the key factors that are estimated to fuel the growth of the global regenerative medicine market in the next few years. In addition, the increasing funding by government bodies and development of new and innovative products are anticipated to supplement the growth of the overall market in the next few years.

On the flip side, the ethical challenges in the stem cell research are likely to restrict the growth of the global regenerative medicine market throughout the forecast period. In addition, the stringent regulatory rules and regulations are predicted to impact the approvals of new products, thus hampering the growth of the overall market in the near future.

Global Regenerative Medicine Market: Market Potential

The growing demand for organ transplantation across the globe is anticipated to boost the demand for regenerative medicines in the next few years. In addition, the rapid growth in the geriatric population and the significant rise in the global healthcare expenditure is predicted to encourage the growth of the market. The presence of a strong pipeline is likely to contribute towards the markets growth in the near future.

Global Regenerative Medicine Market: Regional Outlook

In the past few years, North America led the global regenerative medicine market and is likely to remain in the topmost position throughout the forecast period. This region is expected to account for a massive share of the global market, owing to the rising prevalence of cancer, cardiac diseases, and autoimmunity. In addition, the rising demand for regenerative medicines from the U.S. and the rising government funding are some of the other key aspects that are likely to fuel the growth of the North America market in the near future.

Furthermore, Asia Pacific is expected to register a substantial growth rate in the next few years. The high growth of this region can be attributed to the availability of funding for research and the development of research centers. In addition, the increasing contribution from India, China, and Japan is likely to supplement the growth of the market in the near future.

Global Regenerative Medicine Market: Competitive Analysis

The global market for regenerative medicines is extremely fragmented and competitive in nature, thanks to the presence of a large number of players operating in it. In order to gain a competitive edge in the global market, the key players in the market are focusing on technological developments and research and development activities. In addition, the rising number of mergers and acquisitions and collaborations is likely to benefit the prominent players in the market and encourage the overall growth in the next few years.

Some of the key players operating in the regenerative medicine market across the globe are Vericel Corporation, Japan Tissue Engineering Co., Ltd., Stryker Corporation, Acelity L.P. Inc. (KCI Licensing), Organogenesis Inc., Medtronic PLC, Cook Biotech Incorporated, Osiris Therapeutics, Inc., Integra Lifesciences Corporation, and Nuvasive, Inc. A large number of players are anticipated to enter the global market throughout the forecast period.

To know more about the table of contents, you can click @https://www.tmrresearch.com/sample/sample?flag=T&rep_id=1889

About TMR Research

TMR Research is a premier provider of customized market research and consulting services to busi-ness entities keen on succeeding in todays supercharged economic climate. Armed with an experi-enced, dedicated, and dynamic team of analysts, we are redefining the way our clients conduct business by providing them with authoritative and trusted research studies in tune with the latest methodologies and market trends.

Originally posted here:
Regenerative Medicine Market Poised to Garner Maximum Revenues During 2025 - The Think Curiouser

AllTheResearchs latest research report provides an overview of theRegenerative Medicine market with segmentation, regional analysis and discussion of important industry trends, market share estimates and profiles of the leading key players. The identified trends that are very helpful for business decisions. The Regenerative Medicine Industry report is a valuable source of guidance for the new and prominent growths of the enterprise, the competitive evaluation, and nearby assured analysis for the reviewing size.

The global Regenerative Medicine market was valued at US$ 13.56 Mn in 2018 and is expected to reach US$ 55.67 Mn in 2026, growing at a CAGR of 23% during the forecast period.

Request for Sample with Complete TOC and Figures & Graphs @ https://www.alltheresearch.com/sample-request/232

Company Profiles mapped in Regenerative Medicine market with Competitive Intelligence:

Market Segmentation by Type, Application and Region

Based on Product Type:

Based on Application:

The Global Regenerative Medicine market analyses and researches the Regenerative Medicine development status and forecast in the United States, Europe, China, Japan, Southeast Asia, India and Central and South America. The Global Regenerative Medicine Market focuses on global major leading industry players providing information such as company profiles, product picture and specification, capacity, production, price, cost, revenue, and contact information. Upstream raw materials and equipment and downstream demand analysis is also carried out.

The Regenerative Medicine industry development trends and marketing channels are analyzed. Finally, the feasibility of new investment projects is assessed, and overall research conclusions offered. The Regenerative Medicine Market report provides key statistics on the market status of the Regenerative Medicine manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the industry.

Any questions, Lets discuss with the analyst @ https://www.alltheresearch.com/speak-to-analyst/232

How Report will help you to make decisions for business:

Browse report along with TOC, Table & figures, research methodology and many more @ https://www.alltheresearch.com/report/232/Regenerative Medicine

About AllTheResearch:

AllTheResearch was formed with the aim of making market research a significant tool for managing breakthroughs in the industry. As a leading market research provider, the firm empowers its global clients with business-critical research solutions. The outcome of our study of numerous companies that rely on market research and consulting data for their decision-making made us realise, that its not just sheer data-points, but the right analysis that creates a difference.While some clients were unhappy with the inconsistencies and inaccuracies of data, others expressed concerns over the experience in dealing with the research-firm. Also same-data-for-all-business roles was making research redundant. We identified these gaps and built AllTheResearch to raise the standards of research support.

FOR ALL YOUR RESEARCH NEEDS, REACH OUT TO US AT:

Contact Name: Rohan S.

Email:[emailprotected]

Phone: +1 (407) 768-2028

See more here:
Regenerative Medicine Market By Key Players, Product And Production Information Analysis And Forecast To 2026 - PRnews Leader

Over the last three months I served on the Patient and Medical Advisory Committee for Prop. 14, which will renew support for the California Institute for Regenerative Medicine (CIRM).

It has been an honor and privilege to advocate for CIRM, because the research, education, and clinical trials it supports will save lives and reduce suffering. Were a diverse group, including patients, advocates, scientists, and students - brought together by the power of a state agency that has enabled a cure for children born without an immune system - so called bubble babies, and treatments for blindness and cancer.

In addition to a possible cure for diabetes, more than 90 other regenerative treatments and cures are in clinical trials. It is impossible to argue with these accomplishments.

Given that, some will argue against the economics of supporting CIRM through Prop. 14, which will involve the sale of $5.5 billion in bonds over the next 20 years. Contrast that to the $300 billion per year spent in California on healthcare.

Even if the only thing that comes from CIRM support is a cure for diabetes, it will pay for itself many times over, given that diabetes cost California $30 billion per year. But CIRM wont just enable a cure for diabetes - treatments and cures are being developed for dozens of other chronic diseases and conditions.

Can we afford Prop. 14 now, in the middle of the COVID-19 recession? We can. Bond repayments wont start for five years. After that, state revenue stimulated by CIRM will cover bond payments until 2030. At the same time, renewing support of CIRM will create 100,000 jobs. That is exactly the sort of stimulus we need right now.

View post:
Letters to the Editor: We can afford Prop. 14; Voting for Jordan Cunningham; Poll workers should be tested before, after election - Santa Maria Times

Over the last three months I served on the Patient and Medical Advisory Committee for Prop. 14, which will renew support for the California Institute for Regenerative Medicine (CIRM).

It has been an honor and privilege to advocate for CIRM, because the research, education, and clinical trials it supports will save lives and reduce suffering. Were a diverse group, including patients, advocates, scientists, and students - brought together by the power of a state agency that has enabled a cure for children born without an immune system - so called bubble babies, and treatments for blindness and cancer.

In addition to a possible cure for diabetes, more than 90 other regenerative treatments and cures are in clinical trials. It is impossible to argue with these accomplishments.

Given that, some will argue against the economics of supporting CIRM through Prop. 14, which will involve the sale of $5.5 billion in bonds over the next 20 years. Contrast that to the $300 billion per year spent in California on healthcare.

Even if the only thing that comes from CIRM support is a cure for diabetes, it will pay for itself many times over, given that diabetes cost California $30 billion per year. But CIRM wont just enable a cure for diabetes - treatments and cures are being developed for dozens of other chronic diseases and conditions.

Can we afford Prop. 14 now, in the middle of the COVID-19 recession? We can. Bond repayments wont start for five years. After that, state revenue stimulated by CIRM will cover bond payments until 2030. At the same time, renewing support of CIRM will create 100,000 jobs. That is exactly the sort of stimulus we need right now.

Originally posted here:
Letters to the Editor: We can afford Prop. 14 - Hanford Sentinel

The report on Global Orthopedic Regenerative Medicine Market is a dependable point of reference heralding high accuracy business decisions on the basis of thorough research and observation by seasoned research professionals at CMI Research. The report on global Orthopedic Regenerative Medicine market evidently highlights the causal factors such as demand analysis, trend examination, and technological milestones besides manufacturing activities that have been systematically touched upon to instigate systematic growth projection.

This CMI Research report on global Orthopedic Regenerative Medicine market systematically studies and follows noteworthy progresses across growth trends, novel opportunities as well as drivers and restraints that impact growth prognosis.

Free Sample Report + All Related Graphs & Charts @:https://www.coherentmarketinsights.com/insight/request-sample/3566

Which market players and aspiring new entrants may witness seamless entry?

Curasan, Inc., Carmell Therapeutics Corporation, Anika Therapeutics, Inc., Conatus Pharmaceuticals Inc., Histogen Inc., Royal Biologics, Ortho Regenerative Technologies, Inc., Swiss Biomed Orthopaedics AG, Osiris Therapeutics, Inc., and Octane Medical Inc.

Predicting Scope: Global Orthopedic Regenerative Medicine Market, 2020-2027

Elaborate research proposes global Orthopedic Regenerative Medicine market is likely to experience an impressive growth through the forecast span, 2020-2027, ticking a robust CAGR of xx% USD. The Orthopedic Regenerative Medicine market is anticipated to demonstrate a whopping growth with impressive CAGR valuation. The Orthopedic Regenerative Medicine market is also likely to maintain the growth spurt showing signs of steady recovery.

For appropriate analysis of all the market relevant information as well emerging trends and historical developments in the Orthopedic Regenerative Medicine market, CMI Research has referred to various primary and secondary research practices and contributing factors.

Regional Overview: Global Orthopedic Regenerative Medicine Market

The report specifically sheds light upon note-worthy business discretion, popular trends investment probabilities aligning with budding opportunities as well as breakthrough developments in policies and monetary inclination echoing investor preferences in Orthopedic Regenerative Medicine space.

Competitive Landscape: Global Orthopedic Regenerative Medicine Market

Further in the report, readers are presented with minute details pertaining to significant company profiles, product development, on pricing, production and vital information on raw material and equipment developments also form crucial report contents in this CMI Research report.

Have Any Query? Ask Our Expert @: https://www.coherentmarketinsights.com/insight/request-customization/3566

Segmentation Based on Orthopedic Regenerative Medicine Market Types:

By Procedure Cell TherapyTissue EngineeringBy Cell TypeInduced Pluripotent Stem Cells (iPSCs)Adult Stem CellsTissue Specific Progenitor Stem Cells (TSPSCs),Mesenchymal Stem Cells (MSCs)Umbilical Cord Stem Cells (UCSCs)Bone Marrow Stem Cells (BMSCs)By SourceBone MarrowUmbilical Cord BloodAdipose TissueAllograftsAmniotic FluidBy ApplicationsTendons RepairCartilage RepairBone RepairLigament RepairSpine RepairOthers

Global Orthopedic Regenerative Medicine Market Size & Share, By Regions and Countries/Sub-regions:

Asia Pacific: China, Japan, India, and Rest of Asia Pacific

Europe: Germany, the UK, France, and Rest of Europe

North America: the US, Mexico, and Canada

Latin America: Brazil and Rest of Latin America

Middle East & Africa: GCC Countries and Rest of Middle East & Africa

The regional analysis segment is a highly comprehensive part of the report on the global Orthopedic Regenerative Medicine market. This section offers information on the sales growth in these regions on a country-level Orthopedic Regenerative Medicine market.

The historical and forecast information provided in the report span between2020 and 2027. The report provides detailed volume analysis and region-wise market size analysis of the market.

Report Investment, a Priority: Explains CMI Research

This report also helps market participants to organize R&D activities aligning with exact market requirements

The report resonates critical findings on decisive factors such as downstream needs and requirement specifications as well as upstream product and service development

The report aids in reader comprehension of the market based on dual parameters of value and volume.

This CMI Research initiated research output on Orthopedic Regenerative Medicine market is a ready-to-refer handbook of noteworthy cues for easy adoption by market players and stakeholders

CMI Research skillfully underpins a vivid segment analysis of the global Orthopedic Regenerative Medicine market, rendering appropriate inputs about the revenue generation capabilities of each segment.

Buy this research report @: https://www.coherentmarketinsights.com/insight/buy-now/3566

Thanks for reading our report. If you have any further questions, please contact us. Our team will provide you with the report tailored to your needs.

About Us:

Coherent Market Insightsis a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contacts Us: +1-206-701-6702Email:[emailprotected]Web:https://www.coherentmarketinsights.com/

See more here:
Covid-19 Impact On Orthopedic Regenerative Medicine Market 2020 Future Development, Manufacturers, Trends, Share, Size And Forecast to 2027 |...

After kicking off the Prescription Drug User Fee Act (PDUFA) reauthorization process in July, the US Food and Drug Administration (FDA) has released the first set of meeting summaries in its ongoing negotiations with industry that will shape its prescription drug review program from FY2023-2027.The meeting summaries, while brief, provide insights into what FDA and industry hope to get out of the multi-billion-dollar agreement, with representatives from government and industry alike agreeing that the exploding field of advanced biologic therapies must be a priority. In some other areas, though, the wish lists diverged. (RELATED: PDUFA VII: FDA, industry preview their reauthorization wish lists, Regulatory Focus 23 July 2020).Steering committeeThe PDUFA reauthorization steering committee met three times in September to hash out the ground rules for the negotiations and review the major topics and proposals both sides will work through via designated working groups.FDA and industry both noted the impact of the COVID-19 pandemic on the agency and the reauthorization process at the first meeting on 15 September.Despite historic workload and operating challenges in the time period, the steps taken in PDUFA VI to protect the program from financial uncertainty have proven critical and important to maintaining FDAs operations, FDA said.During the meeting, FDA pitched six areas it wants to focus on for PDUFA VII: digital health and informatics, postmarket, CBER-specific enhancements, pre-market, regulatory decision tools and finance.Industry, on the other hand, expressed interest in build[ing] upon past user fee agreements and to ensure FDA and industry can mutually keep pace with scientific development. Topics presented by industry include: strengthening scientific dialogue, enhancing patient-centric drug review, supporting the next wave of advanced biologic therapies, modernizing regulatory evidence generation, advancing digital and IT technologies, enhancing innovation in quality and manufacturing, and optimizing FDA infrastructure, staffing, and resources.Industry also said it was keen on adopting some of the lessons from the COVID-19 pandemic and translating them into improved processes going forward.During the next steering committee meeting on 22 September, FDA and industry reviewed the overall timeline for reauthorization and the two sides sought clarification on each others proposed topics. The following week the committee met again and reviewed the timeline for communicating with Congress, agreed to topic assignments and looked at some of the overlap between the agencys COVID-19 response and PDUFA interests.CBER subgroupIncreased support for FDAs Center for Biologics Evaluation and Research (CBER) is set to be a focus for both FDA and industry in the negotiations.FDA told industry at the first CBER breakout meeting that it would like to see enhanced resources for its cell and gene therapy program, which has been overwhelmed by an influx of applications and meeting requests in recent years.FDA noted that its new regenerative medicine advanced therapy (RMAT) designation program has seen exponential growth and is now outpacing breakthrough therapy designations in the Office of Tissues and Advanced Therapies (OTAT), despite not receiving any dedicated resources for the fledgling program.With more resources, FDA told industry that it could spend more time on cell and gene therapy submissions, provide more opportunities for engagement and develop policy and guidance for sponsors. FDA also said it will seek dedicated resources for the RMAT program under PDUFA VII.Industry suggested three CBER-related commitments it would like to work into the reauthorization agreement, including workshops and guidance on the use of sponsor-specific prior knowledge in gene therapy submissions, evidentiary standards for RMAT designation and gene therapy manufacturing issues.Industry would like a public workshop to focus on key learnings from the RMAT program resulting in an update to the RMAT guidance, including potential uses of Real World Evidence (RWE) for regulatory decision making, FDA writes, noting that meaningful guidance on the matter may be difficult to develop due to the limited number of approved cell and gene therapy products and the fact that there have not been any products approved to date with RMAT designation.For gene therapy manufacturing, industry specifically said it would like to explore whether submitting portions of a chemistry, manufacturing and controls (CMC) module could facilitate biologics license approval (BLA) review. FDA said it has concerns that a partial submission could actually slow approval down if development is ongoing but agreed to carry the discussion forward.Regulatory decision toolsOn 29 September, the regulatory decision tools subgroup met for the first time, with FDA and industry reviewing potential areas of enhancement and agreeing to a schedule for the next several meetings.FDA raised four topics it would like to tackle in PDUFA VII, including model-informed drug development (MIDD), complex innovative trial designs (CID), patient-focused drug development (PFDD), and advancing translational models and tools for drug development (ATMT).For MIDD, FDA said its goal is to build on the lessons learned during PDUFA VI and to ensure the programs sustainability. Doing so would require public engagement and the development of comprehensive end-to-end guidance, which FDA said would necessitate increased staffing.Digital health and informaticsFDA and industry began discussions aimed at enhancing the use of digital health and informatics technologies under PDUFA VII on 30 September.FDA pitched three topics for discussion at the meeting, including a proposal for an integrated cloud-based technology environment, a framework for leveraging digital health technology-generated data in submissions, and CBER IT modernization.PremarketFDA and industry addressed several premarket issues in the first meeting of the premarket subgroup, including user related risk analysis (URRA) and human factor (HF) protocol review and developing efficacy endpoints for rare diseases.FDA proposed increasing the user fee timeline for reviewing HF protocols and said the current goals will be unsustainable in the future due to increasing volume and complexity of HF submissions. The two sides discussed the creation of a new user fee goal and timeline for review of URRA.FinanceAt the first of two finance subgroup meetings, FDA presented a host of goals for PDUFA VII: To enhance the operational capabilities, efficacy, and agility of the PDUFA program. FDA proposed continuing to advance resource capacity planning, updating the inflation adjustment to accurately account for program costs, enhancing flexibility in the operating reserve, eliminating a problematic limitation on allowable expenditures, streamlining annual reporting requirements, and implementing technical fixes.Industry representatives, however, stressed that their goal is to build on the enhancements made in PDUFA VI and to improve on user fee resource management, hiring and retention of review staff and performance reporting.During the second finance meeting, FDA and industry looked at a proposal to clarify the maximum and minimum amount of operating reserves to be maintained each year and a proposal to further implement the resource capacity planning (RCP) capability instituted in PDUFA VI.Stakeholder meetingFDA also released a meeting summary from the first round of stakeholder discussions. More than 60 stakeholder organizations, including patient groups, consumer representatives, public health advocates and medical associations, registered to attend the meeting, though a third of those registered did not attend.Some of the themes frequently cited by stakeholders included enhancing the incorporation of patient voice in drug development and regulatory decision making, modernizing FDAs infrastructure, ensuring FDA has adequate resources to recruit and retain qualified staff including in the areas of cell and gene therapy, increasing the strength and reach of patient and rare disease programs including improving diversity in clinical trials and patient engagement, enhancing FDAs use of regulatory science (e.g. COAs, MIDD, RWE), and improving the integration of and guidance for the use of real-world evidence (RWE), FDA reported. Stakeholders also raised decentralized trials and lessons learned during the COVID-19 pandemic as topics for future discussions.FDA tasked stakeholders with identifying their top issues for further discussion and said it would survey them to rank the topics on the agreed to shortlist.FDA

See original here:
PDUFA VII: FDA and industry set priorities in first round of negotiations - Regulatory Focus

At the very heart of our Biblical tradition is this commandment from the Book of Leviticus: You shall not stand idly by the blood of your fellow. (Leviticus 19:16)

If we see our sisters or brothers in danger, our job is simple: Provide that help, come to their aid, do what is in our power to protect them and save them.

In the midst of a global pandemic, we feel the call to protect and promote the health and well-being of others even more urgently. Right now, we hear the call to uphold the ultimate Jewish value of pikuach nefesh (saving a life).

Sometimes, we live out that value in an immediate way. We donate blood today, which can save lives in real time. We provide support for basic needs to ensure that people in our community have enough to eat right now. But if we truly wish to move the needle in the work of pikuach nefesh, we must also provide resources to fund research over many years, even decades, that will, ultimately, yield dramatic results.

To truly make a difference, to be Gods partners in bringing healing to the world, we must not stand idly by in both immediate and long-term ways.

California voters have an opportunity to do just this by voting yes on Proposition 14, which will advance the California Institute of Regenerative Medicines stem cell research to help those who are affected by ailments including heart disease, diabetes, Alzheimers, Parkinsons disease, sickle cell disease, spinal cord injuries, Covid-19, and so many other chronic illnesses and injuries.

Funding for this important and vital medical research helps save lives, and it will provide immediate economic stimulus, as well. Even as it funds long-term strategies to alleviate human suffering, Prop. 14 will create jobs during this challenging time. Recent studiessuggest that Prop. 14 would generate approximately $20 billion in increased economic activity in California, yielding more than 100,000 new jobs at every level. This far surpasses Prop. 14s estimated cost of $5.5 billion in bonds.

Critics of the proposition question the need for such funding on a state level today. They argue that Proposition 71, the initiative that originally created the California Institute of Regenerative Medicine, was passed in 2004 only because President George W. Bush had banned federal funding for stem cell research. Now that federal funding for stem cell research is allowed, the critics charge, its no longer Californias responsibility to fund such research; private and federal funding should be used to continue this important work.

However, relying on federal and private funds is too risky. Many in our country wish to stifle and limit stem cell research on religious grounds. Far more importantly, Jewish law on this matter is unequivocal: stem cell research is not just permitted, but, arguably, required as a matter of pikuach nefesh. Numerous halachic authorities have made this clear. It should, therefore, come as no surprise that some of the most exciting work in stem cell research is currently being done in Israel.

Medical experts agree that stem cell research and therapies will save lives and alleviate human suffering. In fact, it already has. One example is the stem cell work Dr. Donald Kohn at UCLA conducted to cure ADA-SCID bubble baby disease.

This work is too important for us to leave it to chance or to allow it to be cut off or limited.

We see Prop. 14s opportunity to provide such resources for life-saving research as a blessing, the fulfillment of core Jewish values.

Just one chapter before the commandment to not stand idly by, our Torah reminds us that the purpose of mitzvot, the very goal of Judaism, is to enhance life. We are commanded: in the pursuit of My laws and statutes you shall live. (Leviticus 18:5) The Rabbis of the Talmud interpret this verse to mean that the ultimate value, above all else, is life itself.

To be sure, it will take many years to realize the promise of current research. But like the well-known story of Honi, who came upon an old man planting a tree that would not bear fruit for another 70 years, we recognize that our efforts are not for ourselves alone. Just as our ancestors sacrificed so that our lives would be better, we commit ourselves to doing the same for our descendants.

The voices of our sisters and brothers cry out to us: friends and family members with diabetes; co-workers fighting against cancer; loved ones slipping away due to the cruel ravages of Alzheimers.

They call out to us in their pain. They are searching for hope.

We cannot stand idly by. We must generously sacrifice so that they and subsequent generations might live and be well.

There are quite literally lives to be saved. Join us by voting yes on Prop, 14 on Nov. 3.

Read more from the original source:
We can't stand idly by: Vote 'yes' on Prop. 14 for stem cell research - The Jewish News of Northern California

Global Market Vision has published a newly innovative statistical data, titled as Regenerative Medicine Market. It is a valuable source of statistical data for Regenerative Medicine market and includes accurate information, which uses primary and secondary research techniques. The research analyst provides comprehensive data, which enhances the growth of the industries. This report focuses on the basic requirement strategies of the businesses, which helps to enlarge the productivity. Additionally, it offers different market segments, such as application, types, size, end users, cost etc.

Get Sample Copy (Including FULL TOC, Graphs and Tables) of this report @: https://www.globalmarketvision.com/sample_request/10671

It includes the research studies about the current trends in different sectors on the basis of their scope. The analyst of this report focuses on the static and dynamic pillars of the industries, for basic understanding of the strategies. In addition to this, it identifies the drivers and opportunities for the development of the businesses. Additionally, it focuses on restraints to analyze the issues from the existing business strategies. It focuses on the various aspects, such as application areas, platforms, and leading players operating across the globe.

Major Companies Profiled in this Report Includes: DePuy Synthes, Medtronic, ZimmerBiomet, Stryker, Acelity, MiMedx Group, Organogenesis, UniQure, Cellular Dynamics International, Osiris Therapeutics, Vcanbio, Gamida Cell, Golden Meditech, Cytori, Celgene, Vericel Corporation, Guanhao Biotech, Mesoblast, Stemcell Technologies, Bellicum Pharmaceuticals.

This statistical report is the comprehensive analysis of different barriers of Regenerative Medicine market. The detailed description of the historical data, current scenario and future predictions have been provided in the report. It gives accurate data of leading companies, which promotes the insights, to make great decisions in the businesses. In this report, you will also find additional data about the economics of the Regenerative Medicine market.

Global Regenerative Medicine Market Segmentation:

By Type/Product, Regenerative Medicine market has been segmented into: Cell Therapy, Tissue Engineering, Biomaterial, Other

By Application/End User, Regenerative Medicine has been segmented into: Dermatology, Cardiovascular, CNS, Orthopedic, Others

Regions Covered in the Global Regenerative Medicine Market: The Middle East and Africa (GCC Countries and Egypt) North America (the United States, Mexico, and Canada) South America (Brazil etc.) Europe (Turkey, Germany, Russia UK, Italy, France, etc.) Asia-Pacific (Vietnam, China, Malaysia, Japan, Philippines, Korea, Thailand, India, Indonesia, and Australia)

The global regions such as, North America, Latin America, Europe, Japan, and India are considered on the basis of the manufacturing, productivity, size, and revenue. This report is summarized with the competitive landscape along with the recent developments in Regenerative Medicine Market sectors for growth of the businesses.

Hurry Up! Get Up to 20% Discount on this Report@: https://www.globalmarketvision.com/check-discount/10671

The reports conclusion leads into the overall scope of the global market with respect to feasibility of investments in various segments of the market, along with a descriptive passage that outlines the feasibility of new projects that might succeed in the global Regenerative Medicine market in the near future. The report will assist understand the requirements of customers, discover problem areas and possibility to get higher, and help in the basic leadership manner of any organization. It can guarantee the success of your promoting attempt, enables to reveal the clients competition empowering them to be one level ahead and restriction losses.

Global market research objectives:

Major questions addressed through this global research report:

Table of Content (TOC):

Chapter 1 Introduction and Overview

Chapter 2 Industry Cost Structure and Economic Impact

Chapter 3 Rising Trends and New Technologies with Major key players

Chapter 4 Global Regenerative Medicine Market Analysis, Trends, Growth Factor

Chapter 5 Regenerative Medicine Market Application and Business with Potential Analysis

Chapter 6 Global Regenerative Medicine Market Segment, Type, Application

Chapter 7 Global Regenerative Medicine Market Analysis (by Application, Type, End User)

Chapter 8 Major Key Vendors Analysis of Regenerative Medicine Market

Chapter 9 Development Trend of Analysis

Chapter 10 Conclusion

Place a Direct Order Of this Report: https://www.globalmarketvision.com/checkout/?currency=USD&type=single_user_license&report_id=10671

Note In order to provide more accurate market forecast, all our reports will be updated before delivery by considering the impact of COVID-19.

Any special requirements about this report, please let us know and we can provide custom report.

We are always happy to assist you on your queries: sales@globalmarketvision.com

Global Market Vision: http://www.globalmarketvision.com/

Continued here:
Regenerative Medicine Market Witnessing Significant Demand in the Global Market During 2020 2027 - Bipartisan Millennial

Colorado State University is no stranger to innovation, and in the past fiscal year, faculty, students, and staff received a record 69 new international and U.S. patents. These came from a similarly record-breaking 177 patent applications.

This feat put CSU, for the first time ever, on the National Academy of Inventors top 100 list of international universities for U.S. patents.

University patents ignite a culture of growth and innovation which in turn stimulates the economy, Jessica Landacre, executive director at the Intellectual Property Owners Association, which co-authored the NAIs report, said in a statement. Added NAIs President Paul Sanberg: The institutions included in this years report are leading innovation worldwide through their encouragement of academic discovery and invention.

The new patents were issued to researchers and inventors in the College of Agricultural Sciences; College of Business; Walter Scott, Jr. College of Engineering; College of Liberal Arts; College of Natural Sciences; College of Veterinary Medicine and Biomedical Sciences, and Facilities Management.

These patents have come through the Universitys technology transfer office, CSU Ventures. Technology transfer provides an avenue that helps to highlight important translational research at CSU and how it positively impacts peoples lives, locally and globally, said Sarah Hibbs-Shipp, director of outreach and communications for CSU Ventures. It also supports the land-grant mission of CSU.

In 2020, CSU Ventures selected Dr. Chris Orton, professor in the Department of Clinical Sciences, as the recipient of the Innovative Excellence Award. A leading authority in veterinary cardiovascular surgery, Orton is known for launching the first veterinary open-heart surgery program in the world.

One of Ortons patented technologies is licensed to Abbott Laboratories and contributed to the design of the companys Tendyne Transcatheter Mitral Valve Implantation system for human use. The system is approved for use in Europe, and is currently in review with the U.S. Food and Drug Administration. This life-changing therapy offers patients with significant mitral regurgitation a minimally invasive alternative to open-heart valve replacement surgery.

In addition to obtaining patents, faculty are also launching new startup companies with their innovations. Five were founded this past year with CSU intellectual property, with the assistance of CSU Ventures.

Startup companies are often the best path forward to bringing new technology to the marketplace, said Todd Headley, vice president of CSU Ventures. They also create jobs and have a positive impact on economic development.

Of the five startups, four of them were founded by CSU faculty and staff.

Of note, a COVID-related device technology developed by CSU researchers Brian Geiss of the Department of Microbiology, Immunology and Pathology; Chuck Henry of the Department of Chemistry; and David Dandy, of the Department of Chemical and Biological Engineering, was licensed to Quara Devices Ic. for further development. Ken Reardon of the Department of Chemical and Biological Engineering is the chief science officer of Quara Devices and helped initiate the licensing deal. The hope is that this small, inexpensive virus-detection technology will serve as the basis of a new product that could compete with standard diagnostic testing for the coronavirus that causes COVID-19.

In all, CSU investigators are currently working on more than 44 COVID-related projects.

These are wonderful demonstrations of how members of the CSU community were able to pivot their research and focus to solve real world, active problems, fully embodying the land-grant mission, Hibbs-Shipp said.

Link:
CSU innovators break record with 69 new patents in the past year - Source